Иммунитет после бустера
Dec. 5th, 2021 09:17 pm![[personal profile]](https://www.dreamwidth.org/img/silk/identity/user.png){kind=small}
chuka_lisРабота от израильтян. Привитых ранее файзером, бустировали либо файзером же, либо джонсоном, и сравнивали состояние иммунитета.
В обоих вариантах иммунитет хорошо стимулировался. В первом, пожалуй, был лучше (и быстрее) антительный ответ, во втором варианте- более реактивными на выделение медиатором оказывались Т клетки.
Да, сравнивали как на оригинальный штамм, так и на бету (что вроде бы неплохо уходит от иммунитета) и дельту.
Судя по результатам, защищать должно неплохо и от вариантов.
Данные по показателям иммунитета за 2 и 4 недели после бустера, конечно, со временем могут ответы ослабляться.
Но пока что результаты обнадеживающие.
Previous studies have reported that a third dose of the BNT162b2 (Pfizer) COVID-19 vaccine increased antibody titersand protective efficacy1,2. Here we compare humoral and cellular immune responses in 65individuals who were vaccinated with the BNT162b2 vaccine and were boosted after at least 6 months with either Ad26.COV2.S3(Johnson & Johnson; N=41) or BNT162b24(Pfizer; N=24)(Table S1). Pseudovirus neutralizing antibody responses were detectable but lowat six months following BNT162b2 vaccination, consistent with previous reports showing that serum antibody titers decline sharplyfollowing BNT162b2vaccination1,5. Ad26.COV2.S boosting increased median neutralizing antibody titers to the WA1/2020, delta, and beta variants to 1,462, 1,009, and 899 at week 2 following the boost, respectively, and these titers further increased2.46-, 2.18-, and 2.14-foldto 3,597, 2,198, and 1,924 at week 4 following the boost (Fig. 1A, Table S2). BNT162b2boosting increased median neutralizing antibody titers to the WA1/2020, delta, and beta variants to 7,554, 2,978, and 1,865at week 2 following the boost, respectively, and these titers declined to 5,553, 1,968, and 1,576at week 4 following the boost (Fig. 1A, Table S2).Ad26.COV2.S boosting increased median receptor binding domain (RBD)-specific antibody titers by ELISA to the WA1/2020, delta, and beta variants to 11,264, 10,817, and 5,375 at week 2 following the boost, respectively, and these titers further increased to16,311, 13,118, and 10,279 at week 4 following the boost (Fig. 1B). BNT162b2 boosting increased median RBD-specific ELISA titers to the WA1/2020, delta, and beta variants to 30,730, 26,398, and 14,725at week 2 following the boost, respectively, and these titers declined to 14,747, 13,037, and 7,230 at week 4 following the boost (Fig. 1B). Similar trends were observed with an electrochemiluminescence binding antibody assay (ECLA )(Fig. S1). These data show that BNT162b2 boosting ledto peak antibody titers at week 2, whereas Ad26.COV2.S led to peak antibody titers at week4or later. Binding and neutralizing antibody titers were comparable at week 4 following Ad26.COV2.S and BNT162b2 boosts.Median S-specific IFN-γ CD8+ T cell responses to the WA1/2020, delta, and beta variants were boosted by Ad26.COV2.S to 0.078%, 0.072%, and 0.083%, respectively, and by BNT162b2to 0.026%, 0.031%, and 0.018%, respectively (Fig. 1C). Median S-specificIFN-γCD4+ T cells to the WA1/2020, delta, and beta variants were boosted by Ad26.COV2.S to 0.095%, 0.101%, and 0.099%, respectively, and byBNT162b2to 0.052%, 0.043%, and 0.043%, respectively(Fig. 1D). Median RBD-specific memory B cell responses were boosted by Ad26.COV2.S to 0.391% and by BNT162b2 to 0.388% (Fig. S2). RBD-specific B cells exhibited primarily an activated memory phenotype at week 2 following both Ad26.COV2.S and BNT162b2 boosting (Fig. S3).These data demonstrate that both heterologous Ad26.COV2.S and homologous BNT162b2 increased antibody responses in individuals who were vaccinated at least 6 months previously with BNT162b2. Ad26.COV2.S and BNT162b2led to similar antibody titers by week 4 following the boost immunizationbut exhibited different immune kinetics5. Ad26.COV2.S led to greater increases in CD8+ T cell responses thanBNT162b2. However, the durability of these immune responses remain to be determined. These data suggest different immune phenotypes following heterologous (“mix-and-match”) compared with homologous boost strategies for COVID-19.
В обоих вариантах иммунитет хорошо стимулировался. В первом, пожалуй, был лучше (и быстрее) антительный ответ, во втором варианте- более реактивными на выделение медиатором оказывались Т клетки.
Да, сравнивали как на оригинальный штамм, так и на бету (что вроде бы неплохо уходит от иммунитета) и дельту.
Судя по результатам, защищать должно неплохо и от вариантов.
Данные по показателям иммунитета за 2 и 4 недели после бустера, конечно, со временем могут ответы ослабляться.
Но пока что результаты обнадеживающие.
Previous studies have reported that a third dose of the BNT162b2 (Pfizer) COVID-19 vaccine increased antibody titersand protective efficacy1,2. Here we compare humoral and cellular immune responses in 65individuals who were vaccinated with the BNT162b2 vaccine and were boosted after at least 6 months with either Ad26.COV2.S3(Johnson & Johnson; N=41) or BNT162b24(Pfizer; N=24)(Table S1). Pseudovirus neutralizing antibody responses were detectable but lowat six months following BNT162b2 vaccination, consistent with previous reports showing that serum antibody titers decline sharplyfollowing BNT162b2vaccination1,5. Ad26.COV2.S boosting increased median neutralizing antibody titers to the WA1/2020, delta, and beta variants to 1,462, 1,009, and 899 at week 2 following the boost, respectively, and these titers further increased2.46-, 2.18-, and 2.14-foldto 3,597, 2,198, and 1,924 at week 4 following the boost (Fig. 1A, Table S2). BNT162b2boosting increased median neutralizing antibody titers to the WA1/2020, delta, and beta variants to 7,554, 2,978, and 1,865at week 2 following the boost, respectively, and these titers declined to 5,553, 1,968, and 1,576at week 4 following the boost (Fig. 1A, Table S2).Ad26.COV2.S boosting increased median receptor binding domain (RBD)-specific antibody titers by ELISA to the WA1/2020, delta, and beta variants to 11,264, 10,817, and 5,375 at week 2 following the boost, respectively, and these titers further increased to16,311, 13,118, and 10,279 at week 4 following the boost (Fig. 1B). BNT162b2 boosting increased median RBD-specific ELISA titers to the WA1/2020, delta, and beta variants to 30,730, 26,398, and 14,725at week 2 following the boost, respectively, and these titers declined to 14,747, 13,037, and 7,230 at week 4 following the boost (Fig. 1B). Similar trends were observed with an electrochemiluminescence binding antibody assay (ECLA )(Fig. S1). These data show that BNT162b2 boosting ledto peak antibody titers at week 2, whereas Ad26.COV2.S led to peak antibody titers at week4or later. Binding and neutralizing antibody titers were comparable at week 4 following Ad26.COV2.S and BNT162b2 boosts.Median S-specific IFN-γ CD8+ T cell responses to the WA1/2020, delta, and beta variants were boosted by Ad26.COV2.S to 0.078%, 0.072%, and 0.083%, respectively, and by BNT162b2to 0.026%, 0.031%, and 0.018%, respectively (Fig. 1C). Median S-specificIFN-γCD4+ T cells to the WA1/2020, delta, and beta variants were boosted by Ad26.COV2.S to 0.095%, 0.101%, and 0.099%, respectively, and byBNT162b2to 0.052%, 0.043%, and 0.043%, respectively(Fig. 1D). Median RBD-specific memory B cell responses were boosted by Ad26.COV2.S to 0.391% and by BNT162b2 to 0.388% (Fig. S2). RBD-specific B cells exhibited primarily an activated memory phenotype at week 2 following both Ad26.COV2.S and BNT162b2 boosting (Fig. S3).These data demonstrate that both heterologous Ad26.COV2.S and homologous BNT162b2 increased antibody responses in individuals who were vaccinated at least 6 months previously with BNT162b2. Ad26.COV2.S and BNT162b2led to similar antibody titers by week 4 following the boost immunizationbut exhibited different immune kinetics5. Ad26.COV2.S led to greater increases in CD8+ T cell responses thanBNT162b2. However, the durability of these immune responses remain to be determined. These data suggest different immune phenotypes following heterologous (“mix-and-match”) compared with homologous boost strategies for COVID-19.
![[community profile]](https://www.dreamwidth.org/img/silk/identity/community.png){kind=small}